Company intelligence / Profile preview

Abeome

Athens, Georgia, USA

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Abeome is a pre-clinical stage biotechnology company focusing on discovery of first-in-class monoclonal antibodies for asthma, cancer, autoimmune disease, obesity, and hypercholesterolemia using its proprietary AbeoMouse and DiSH technology platforms. Efficacy and animal proof-of-concept for some targets (e.g., anti-PCSK9 antibodies for hypercholesterolemia) have been obtained, but no human clinical data has been reported.

Therapeutic areas: ImmunologyCardiovascularEndocrinologyPulmonologyOncology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Abeome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abeome.

Explore the full profile